These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 32584509)

  • 1. NLRC3 silencing accelerates the invasion of hepatocellular carcinoma cell via IL-6/JAK2/STAT3 pathway activation.
    Kang JH; Li MJ; Luan PP; Jiang DK; Chen YW; Xu X; Yu Q; Xu YW; Su Q; Peng WH; Jian WX
    Cell Biol Int; 2020 Oct; 44(10):2053-2064. PubMed ID: 32584509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long Noncoding RNA HOST2 Promotes Epithelial-Mesenchymal Transition, Proliferation, Invasion and Migration of Hepatocellular Carcinoma Cells by Activating the JAK2-STAT3 Signaling Pathway.
    Wu Y; Yuan T; Wang WW; Ge PL; Gao ZQ; Zhang G; Tang Z; Dang XW; Zhao YF; Zhang JY; Jiang GZ
    Cell Physiol Biochem; 2018; 51(1):301-314. PubMed ID: 30453302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LncRNA 00152 promotes the development of hepatocellular carcinoma by activating JAK2/STAT3 pathway.
    Li SJ; Sui MH; Sun ZX; Zhang WW
    Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1038-1046. PubMed ID: 30779070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circ_0072088 promotes progression of hepatocellular carcinoma by activating JAK2/STAT3 signaling pathway via miR-375.
    Li L; Xiao C; He K; Xiang G
    IUBMB Life; 2021 Sep; 73(9):1153-1165. PubMed ID: 34148288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-17 induces AKT-dependent IL-6/JAK2/STAT3 activation and tumor progression in hepatocellular carcinoma.
    Gu FM; Li QL; Gao Q; Jiang JH; Zhu K; Huang XY; Pan JF; Yan J; Hu JH; Wang Z; Dai Z; Fan J; Zhou J
    Mol Cancer; 2011 Dec; 10():150. PubMed ID: 22171994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The correlation of NLRC3 expression with the progression and prognosis of hepatocellular carcinoma.
    Ma YY; Zhang GH; Li J; Wang SB; Hu ZM; Zhang CW; Li E
    Hum Pathol; 2018 Dec; 82():273-281. PubMed ID: 30081150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of FXR modulates SOCS3/Jak2/STAT3 signaling axis in a NASH-dependent hepatocellular carcinoma animal model.
    Attia YM; Tawfiq RA; Gibriel AA; Ali AA; Kassem DH; Hammam OA; Elmazar MM
    Biochem Pharmacol; 2021 Apr; 186():114497. PubMed ID: 33675775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CircSOD2 induced epigenetic alteration drives hepatocellular carcinoma progression through activating JAK2/STAT3 signaling pathway.
    Zhao Z; Song J; Tang B; Fang S; Zhang D; Zheng L; Wu F; Gao Y; Chen C; Hu X; Weng Q; Yang Y; Tu J; Ji J
    J Exp Clin Cancer Res; 2020 Nov; 39(1):259. PubMed ID: 33234142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DDX5 Silencing Suppresses the Migration of Basal cell Carcinoma Cells by Downregulating JAK2/STAT3 Pathway.
    Quan Z; Zhang BB; Yin F; Du J; Zhi YT; Xu J; Song N
    Technol Cancer Res Treat; 2019; 18():1533033819892258. PubMed ID: 31870221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypoxia-inducible gene 2 promotes the immune escape of hepatocellular carcinoma from nature killer cells through the interleukin-10-STAT3 signaling pathway.
    Cui C; Fu K; Yang L; Wu S; Cen Z; Meng X; Huang Q; Xie Z
    J Exp Clin Cancer Res; 2019 May; 38(1):229. PubMed ID: 31142329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel anti-cancer agent Icaritin suppresses hepatocellular carcinoma initiation and malignant growth through the IL-6/Jak2/Stat3 pathway.
    Zhao H; Guo Y; Li S; Han R; Ying J; Zhu H; Wang Y; Yin L; Han Y; Sun L; Wang Z; Lin Q; Bi X; Jiao Y; Jia H; Zhao J; Huang Z; Li Z; Zhou J; Song W; Meng K; Cai J
    Oncotarget; 2015 Oct; 6(31):31927-43. PubMed ID: 26376676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Norcantharidin inhibits IL-6-induced epithelial‑mesenchymal transition via the JAK2/STAT3/TWIST signaling pathway in hepatocellular carcinoma cells.
    Gao Y; Li W; Liu R; Guo Q; Li J; Bao Y; Zheng H; Jiang S; Hua B
    Oncol Rep; 2017 Aug; 38(2):1224-1232. PubMed ID: 28677802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long non-coding RNA FEZF1-AS1 promotes cell invasion and epithelial-mesenchymal transition through JAK2/STAT3 signaling pathway in human hepatocellular carcinoma.
    Wang YD; Sun XJ; Yin JJ; Yin M; Wang W; Nie ZQ; Xu J
    Biomed Pharmacother; 2018 Oct; 106():134-141. PubMed ID: 29957463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long non-coding RNA TINCR promotes hepatocellular carcinoma proliferation and invasion via STAT3 signaling by direct interacting with T-cell protein tyrosine phosphatase (TCPTP).
    Tang C; Feng W; Bao Y; Du H
    Bioengineered; 2021 Dec; 12(1):2119-2131. PubMed ID: 34057016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo and in vitro effects of microRNA-221 on hepatocellular carcinoma development and progression through the JAK-STAT3 signaling pathway by targeting SOCS3.
    Huang S; Zhou D; Li YX; Ming ZY; Li KZ; Wu GB; Chen C; Zhao YN
    J Cell Physiol; 2019 Apr; 234(4):3500-3514. PubMed ID: 30370582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Celecoxib inhibits interleukin-6/interleukin-6 receptor-induced JAK2/STAT3 phosphorylation in human hepatocellular carcinoma cells.
    Liu Y; Liu A; Li H; Li C; Lin J
    Cancer Prev Res (Phila); 2011 Aug; 4(8):1296-305. PubMed ID: 21490132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of chaperonin containing TCP1, subunit 3 predicts poor prognosis in hepatocellular carcinoma.
    Cui X; Hu ZP; Li Z; Gao PJ; Zhu JY
    World J Gastroenterol; 2015 Jul; 21(28):8588-604. PubMed ID: 26229401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LncRNA TUG1 interacting with miR-144 contributes to proliferation, migration and tumorigenesis through activating the JAK2/STAT3 pathway in hepatocellular carcinoma.
    Lv J; Kong Y; Gao Z; Liu Y; Zhu P; Yu Z
    Int J Biochem Cell Biol; 2018 Aug; 101():19-28. PubMed ID: 29791864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. UBE2S promotes malignant properties via VHL/HIF-1α and VHL/JAK2/STAT3 signaling pathways and decreases sensitivity to sorafenib in hepatocellular carcinoma.
    Wu J; Xu X; Wu S; Shi W; Zhang G; Cao Y; Wang Z; Wu J; Jiang C
    Cancer Med; 2023 Sep; 12(17):18078-18097. PubMed ID: 37563971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fatty acid binding protein 5 promotes tumor angiogenesis and activates the IL6/STAT3/VEGFA pathway in hepatocellular carcinoma.
    Pan L; Xiao H; Liao R; Chen Q; Peng C; Zhang Y; Mu T; Wu Z
    Biomed Pharmacother; 2018 Oct; 106():68-76. PubMed ID: 29957468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.